DK173838B1 - Fremgangsmåde til påvisning af tilstedeværelsen af et blodpladecelleoverfladeantigen - Google Patents
Fremgangsmåde til påvisning af tilstedeværelsen af et blodpladecelleoverfladeantigen Download PDFInfo
- Publication number
- DK173838B1 DK173838B1 DK198804265A DK426588A DK173838B1 DK 173838 B1 DK173838 B1 DK 173838B1 DK 198804265 A DK198804265 A DK 198804265A DK 426588 A DK426588 A DK 426588A DK 173838 B1 DK173838 B1 DK 173838B1
- Authority
- DK
- Denmark
- Prior art keywords
- platelet
- platelets
- immunocomplex
- antibody
- antigen
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- 101710160107 Outer membrane protein A Proteins 0.000 title claims abstract description 11
- 239000000427 antigen Substances 0.000 claims abstract description 75
- 102000036639 antigens Human genes 0.000 claims abstract description 75
- 108091007433 antigens Proteins 0.000 claims abstract description 75
- 210000004027 cell Anatomy 0.000 claims abstract description 53
- 239000007790 solid phase Substances 0.000 claims description 36
- 239000007787 solid Substances 0.000 claims description 32
- 239000011541 reaction mixture Substances 0.000 claims description 29
- 230000036046 immunoreaction Effects 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 238000002372 labelling Methods 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 230000000890 antigenic effect Effects 0.000 claims description 10
- 230000006800 cellular catabolic process Effects 0.000 claims description 10
- 230000002000 scavenging effect Effects 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 claims description 5
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 230000002459 sustained effect Effects 0.000 claims description 5
- 102000023159 Platelet Glycoprotein GPIb-IX Complex Human genes 0.000 claims description 4
- 108010045766 Platelet Glycoprotein GPIb-IX Complex Proteins 0.000 claims description 4
- 230000001235 sensitizing effect Effects 0.000 claims description 3
- 239000012071 phase Substances 0.000 claims 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 1
- 210000001772 blood platelet Anatomy 0.000 description 180
- 210000002381 plasma Anatomy 0.000 description 54
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 27
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 21
- 238000003018 immunoassay Methods 0.000 description 20
- 239000011324 bead Substances 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 238000010911 splenectomy Methods 0.000 description 19
- 230000027455 binding Effects 0.000 description 17
- 238000003556 assay Methods 0.000 description 15
- 239000011230 binding agent Substances 0.000 description 13
- 239000013642 negative control Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 102000003886 Glycoproteins Human genes 0.000 description 12
- 108090000288 Glycoproteins Proteins 0.000 description 12
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 12
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 12
- 230000001684 chronic effect Effects 0.000 description 12
- 229920000136 polysorbate Polymers 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 238000001114 immunoprecipitation Methods 0.000 description 11
- 238000011534 incubation Methods 0.000 description 10
- 238000005063 solubilization Methods 0.000 description 10
- 230000007928 solubilization Effects 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 239000007979 citrate buffer Substances 0.000 description 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 230000000702 anti-platelet effect Effects 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102000018697 Membrane Proteins Human genes 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 241001529936 Murinae Species 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- -1 polyoxyethylene Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000003582 thrombocytopenic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 230000000961 alloantigen Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 206010060935 Alloimmunisation Diseases 0.000 description 3
- 108010032595 Antibody Binding Sites Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 102000008607 Integrin beta3 Human genes 0.000 description 3
- 108010020950 Integrin beta3 Proteins 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 description 3
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000018240 Bone Marrow Failure disease Diseases 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000007392 microtiter assay Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 239000003634 thrombocyte concentrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- IITIZHOBOIBGBW-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(CC)CSC2=C1 IITIZHOBOIBGBW-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000029147 Collagen-vascular disease Diseases 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 108010091326 Cryoglobulins Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 101000986086 Homo sapiens HLA class I histocompatibility antigen, A alpha chain Proteins 0.000 description 1
- 101000986087 Homo sapiens HLA class I histocompatibility antigen, B alpha chain Proteins 0.000 description 1
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000037026 Invasive Fungal Infections Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100174574 Mus musculus Pikfyve gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010035030 Platelet Membrane Glycoprotein IIb Proteins 0.000 description 1
- 102100036851 Platelet glycoprotein IX Human genes 0.000 description 1
- 101710191888 Platelet glycoprotein IX Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000029036 donor selection Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 231100000355 lymphocytotoxic Toxicity 0.000 description 1
- 230000001391 lymphocytotoxic effect Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- ZPIRTVJRHUMMOI-UHFFFAOYSA-N octoxybenzene Chemical compound CCCCCCCCOC1=CC=CC=C1 ZPIRTVJRHUMMOI-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000007925 protein solubilization Effects 0.000 description 1
- 238000001799 protein solubilization Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G02—OPTICS
- G02F—OPTICAL DEVICES OR ARRANGEMENTS FOR THE CONTROL OF LIGHT BY MODIFICATION OF THE OPTICAL PROPERTIES OF THE MEDIA OF THE ELEMENTS INVOLVED THEREIN; NON-LINEAR OPTICS; FREQUENCY-CHANGING OF LIGHT; OPTICAL LOGIC ELEMENTS; OPTICAL ANALOGUE/DIGITAL CONVERTERS
- G02F1/00—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics
- G02F1/29—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the position or the direction of light beams, i.e. deflection
- G02F1/31—Digital deflection, i.e. optical switching
- G02F1/313—Digital deflection, i.e. optical switching in an optical waveguide structure
- G02F1/3131—Digital deflection, i.e. optical switching in an optical waveguide structure in optical fibres
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- G—PHYSICS
- G02—OPTICS
- G02F—OPTICAL DEVICES OR ARRANGEMENTS FOR THE CONTROL OF LIGHT BY MODIFICATION OF THE OPTICAL PROPERTIES OF THE MEDIA OF THE ELEMENTS INVOLVED THEREIN; NON-LINEAR OPTICS; FREQUENCY-CHANGING OF LIGHT; OPTICAL LOGIC ELEMENTS; OPTICAL ANALOGUE/DIGITAL CONVERTERS
- G02F1/00—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics
- G02F1/35—Non-linear optics
- G02F1/3515—All-optical modulation, gating, switching, e.g. control of a light beam by another light beam
- G02F1/3517—All-optical modulation, gating, switching, e.g. control of a light beam by another light beam using an interferometer
- G02F1/3519—All-optical modulation, gating, switching, e.g. control of a light beam by another light beam using an interferometer of Sagnac type, i.e. nonlinear optical loop mirror [NOLM]
-
- G—PHYSICS
- G02—OPTICS
- G02F—OPTICAL DEVICES OR ARRANGEMENTS FOR THE CONTROL OF LIGHT BY MODIFICATION OF THE OPTICAL PROPERTIES OF THE MEDIA OF THE ELEMENTS INVOLVED THEREIN; NON-LINEAR OPTICS; FREQUENCY-CHANGING OF LIGHT; OPTICAL LOGIC ELEMENTS; OPTICAL ANALOGUE/DIGITAL CONVERTERS
- G02F3/00—Optical logic elements; Optical bistable devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Nonlinear Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Optics & Photonics (AREA)
- Rheumatology (AREA)
- Power Engineering (AREA)
- Rehabilitation Therapy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Sampling And Sample Adjustment (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93612586 | 1986-12-01 | ||
| US06/936,125 US4810632A (en) | 1986-12-01 | 1986-12-01 | Cell surface antigen detection method |
| US07/124,905 US5176998A (en) | 1986-12-01 | 1987-11-24 | Cell surface antigen detection method |
| US12490587 | 1987-11-24 | ||
| PCT/US1987/003129 WO1988004432A1 (en) | 1986-12-01 | 1987-11-25 | Cell surface antigen detection method |
| US8703129 | 1987-11-25 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK426588A DK426588A (da) | 1988-07-29 |
| DK426588D0 DK426588D0 (da) | 1988-07-29 |
| DK173838B1 true DK173838B1 (da) | 2001-12-10 |
Family
ID=26823073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198804265A DK173838B1 (da) | 1986-12-01 | 1988-07-29 | Fremgangsmåde til påvisning af tilstedeværelsen af et blodpladecelleoverfladeantigen |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US5176998A (sv) |
| EP (1) | EP0290595B1 (sv) |
| JP (1) | JP2803824B2 (sv) |
| AT (1) | ATE123341T1 (sv) |
| AU (1) | AU594554B2 (sv) |
| DE (1) | DE3751331T2 (sv) |
| DK (1) | DK173838B1 (sv) |
| FI (1) | FI95082C (sv) |
| NO (1) | NO172910C (sv) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5176998A (en) * | 1986-12-01 | 1993-01-05 | The Scripps Research Institute | Cell surface antigen detection method |
| US5525461A (en) * | 1991-11-01 | 1996-06-11 | T Cell Diagnostics, Inc. | Therapeutic and diagnostic methods using total leukocyte surface antigens |
| US5731425A (en) * | 1994-10-28 | 1998-03-24 | Eastman Kodak Company | Polypeptide surface marker for cells |
| US6984526B2 (en) | 1995-02-08 | 2006-01-10 | University Of South Florida | Spectrophotometric method for determining the viability of a sample containing platelets |
| US6330058B1 (en) | 1999-04-14 | 2001-12-11 | University Of South Florida | Spectrophotometric method and apparatus for blood typing |
| US6379903B1 (en) | 1999-10-08 | 2002-04-30 | Sigma-Aldrich Co. | Purification of recombinant proteins fused to multiple epitopes |
| CN102203610A (zh) | 2008-12-01 | 2011-09-28 | 利兰·斯坦福青年大学托管委员会 | 用于检测补体结合性抗体的方法和组合物 |
| WO2012070964A1 (ru) * | 2010-11-22 | 2012-05-31 | Farber Boris Slavinovich | Модифицированные олигопептиды с противораковыми свойствами и способ их получения |
| CN105308457B (zh) | 2013-03-14 | 2018-07-10 | 斯坦福大学托管董事会 | 检测供体特异性抗体的方法和用于实施所述方法的系统 |
| US10527613B2 (en) | 2015-11-10 | 2020-01-07 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarker detection methods and systems and kits for practicing same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342566A (en) * | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4443427A (en) * | 1982-06-21 | 1984-04-17 | Sidney Farber Cancer Institute, Inc. | Monoclonal antibody |
| US4643971A (en) * | 1983-03-11 | 1987-02-17 | Sloan-Kettering Institute | Monoclonal antibodies to human bladder and ureter cancers and method |
| EP0149168B1 (en) * | 1983-12-19 | 1991-04-24 | Daiichi Pure Chemicals Co. Ltd. | Immunoassay |
| US4695538A (en) * | 1984-06-01 | 1987-09-22 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies to cell surface antigens |
| EP0169729A3 (en) * | 1984-07-23 | 1988-08-03 | Becton Dickinson and Company | Recovery of cell receptors |
| US4670394A (en) * | 1984-11-16 | 1987-06-02 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Isolation and culture of adrenal medullary endothelial cells producing blood clotting factor VIII:C |
| US4810632A (en) * | 1986-12-01 | 1989-03-07 | Scripps Clinic And Research Foundation | Cell surface antigen detection method |
| US5176998A (en) * | 1986-12-01 | 1993-01-05 | The Scripps Research Institute | Cell surface antigen detection method |
-
1987
- 1987-11-24 US US07/124,905 patent/US5176998A/en not_active Expired - Lifetime
- 1987-11-25 DE DE3751331T patent/DE3751331T2/de not_active Expired - Lifetime
- 1987-11-25 JP JP63500784A patent/JP2803824B2/ja not_active Expired - Lifetime
- 1987-11-25 AU AU10876/88A patent/AU594554B2/en not_active Expired
- 1987-11-25 AT AT88900625T patent/ATE123341T1/de not_active IP Right Cessation
- 1987-11-25 EP EP88900625A patent/EP0290595B1/en not_active Expired - Lifetime
-
1988
- 1988-07-29 DK DK198804265A patent/DK173838B1/da not_active IP Right Cessation
- 1988-07-29 FI FI883585A patent/FI95082C/sv not_active IP Right Cessation
- 1988-07-29 NO NO883367A patent/NO172910C/no not_active IP Right Cessation
-
1992
- 1992-10-28 US US07/967,449 patent/US5336597A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE3751331T2 (de) | 1996-02-01 |
| FI95082C (sv) | 1995-12-11 |
| DK426588A (da) | 1988-07-29 |
| FI883585A0 (sv) | 1988-07-29 |
| US5336597A (en) | 1994-08-09 |
| ATE123341T1 (de) | 1995-06-15 |
| NO172910B (no) | 1993-06-14 |
| JPH01501571A (ja) | 1989-06-01 |
| NO172910C (no) | 1993-09-22 |
| FI883585A (sv) | 1988-07-29 |
| AU1087688A (en) | 1988-06-30 |
| NO883367L (no) | 1988-07-29 |
| EP0290595A1 (en) | 1988-11-17 |
| FI95082B (sv) | 1995-08-31 |
| NO883367D0 (no) | 1988-07-29 |
| DE3751331D1 (de) | 1995-07-06 |
| DK426588D0 (da) | 1988-07-29 |
| AU594554B2 (en) | 1990-03-08 |
| EP0290595A4 (en) | 1990-12-19 |
| EP0290595B1 (en) | 1995-05-31 |
| US5176998A (en) | 1993-01-05 |
| JP2803824B2 (ja) | 1998-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smith et al. | C4d fixing, luminex binding antibodies—a new tool for prediction of graft failure after heart transplantation | |
| JP5807300B2 (ja) | 試料中のｃ反応性蛋白質の測定方法及び測定試薬 | |
| EP0512301B1 (en) | Method for detecting inflammation | |
| WO1988004432A1 (en) | Cell surface antigen detection method | |
| JPH06505332A (ja) | 総白血球表面抗原を用いた治療法及び診断法 | |
| DK173838B1 (da) | Fremgangsmåde til påvisning af tilstedeværelsen af et blodpladecelleoverfladeantigen | |
| DK174032B1 (da) | Sæt samt fremgangsmåde til immunometrisk dosering, der kan anvendes på hele celler | |
| BRPI0918233B1 (pt) | métodos de triagem para a lesão pulmonar aguda e doença do enxerto contra hospedeiro relacionada à transfusão ou transplante, kits e uso de polipeptídeos | |
| Göbel et al. | Disease activity and autoantibodies to endothelial cells in patients with Wegener's granulomatosis | |
| Kekomäki et al. | A new platelet alloantigen, Tua, on glycoprotein IIIa associated with neonatal alloimmune thrombocytopenia in two families | |
| Pandey et al. | Effects of different sensitization events on HLA alloimmunization in renal transplant cases; a retrospective observation in 1066 cases | |
| JPH03502401A (ja) | ヒト抗Ｒｈ（Ｄ）モノクローナム抗体 | |
| JP2019168403A (ja) | 高安動脈炎の診断方法、診断マーカー及び診断キット | |
| JPH01105160A (ja) | 異常応答リンパ球の検出方法並びにこれに用いる検出用試薬及びキット | |
| Osti et al. | Acute haemolysis by cold antibody during SARS-CoV-2 infection in a patient with Evans syndrome: a case report and literature review | |
| KR890002632B1 (ko) | Atl 바이러스 항체 측정용 시약의 제조방법 | |
| CN108883174B (zh) | 用于鉴定可移植的组织样品的IgG亚型测定 | |
| Inami et al. | Micro-hemagglutination tests for detection of native and single-strand DNA antibodies and circulating DNA antigen | |
| RU2817215C2 (ru) | Способ диагностики аллоиммунной тромбоцитопении новорожденных | |
| Rabellino et al. | Antigen heterogeneity of human B and T lymphocytes. | |
| Boisvert et al. | The detection of platelet antibodies using a modified platelet immunofluorescence test | |
| Vojvodić et al. | HLA antibody screening strategy in patients awaiting kidney transplantation | |
| Duursma | Neutrophil cytoplasmic antibodies: their clinical associations and an improved method for their detection. | |
| FR2573533A1 (fr) | Procede de detection ou de titration d'immunoglobulines dirigees contre un antigene particulier et dispositif pour la mise en oeuvre de ce procede. | |
| Katznelson et al. | AIMS OF CHAPTER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B1 | Patent granted (law 1993) | ||
| PUP | Patent expired |